Four versus six courses of a dose-escalated cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) regimen plus etoposide (megaCHOEP) and autologous stem cell transplantation: Early dose intensity is crucial in treating younger patients with poor prognosis aggressive lymphoma

Cancer

Volumn 106, Issue 1, 2006, Pages 136-145

  Schmitz, Nobert ^a   Kloess, Marita ^b   Reiser, Marcel ^c   Berdel, Wolfgang E ^d   Metzner, Bernd ^e   Dorken, Bernd ^f   Kneba, Michael ^g   Trumper, Lorenz ^h   Loeffler, Markus ^b   Pfreundschuh, Michael ⁱ   Glass, Bertram ^h  

^a AK St Georg ^*  (Germany)

^b UNIVERSITY OF LEIPZIG   (Germany)

^c UNIVERSITY OF COLOGNE   (Germany)

^d UNIVERSITY OF MÜNSTER   (Germany)

^e KLINIKUM OLDENBURG   (Germany)

^f CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^g UNIVERSITY OF KIEL   (Germany)

^h UNIVERSITY MEDICAL CENTER GÖTTINGEN   (Germany)

ⁱ SAARLAND UNIVERSITY   (Germany)

Author keywords

Autologous stem cell transplantation; CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone); Dose intensity; Lymphoma; megaCHOEP (cyclophosphamide, doxorubicin, vincristine, etoposide, and prednisone)

Indexed keywords

CD34 ANTIGEN; COTRIMOXAZOLE; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LACTATE DEHYDROGENASE; PREDNISONE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; VINCRISTINE;

ADULT; ADULT RESPIRATORY DISTRESS SYNDROME; AGED; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER COMBINATION CHEMOTHERAPY; CANCER CONTROL; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOSE RESPONSE; DOSE TIME EFFECT RELATION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; FEMALE; GASTROINTESTINAL SYMPTOM; HUMAN; ILEUS; INFECTION; LACTATE DEHYDROGENASE BLOOD LEVEL; LIVER TOXICITY; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PNEUMOCYSTIS PNEUMONIA; PNEUMONIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; STOMATITIS; TREATMENT OUTCOME;

ADULT; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COMBINED MODALITY THERAPY; CYCLOPHOSPHAMIDE; DOXORUBICIN; DRUG ADMINISTRATION SCHEDULE; ETOPOSIDE; FEMALE; HUMANS; LYMPHOMA; MALE; MIDDLE AGED; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PREDNISONE; PROSPECTIVE STUDIES; SURVIVAL RATE; TRANSPLANTATION, AUTOLOGOUS; TREATMENT OUTCOME; VINCRISTINE;

EID: 29744451768     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21588     Document Type: Article

References (21)

1. [no authors listed]. A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med. 1993;329:987-994.
2. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimes for advanced non-Hodgkin's lymphoma. N Engl J Med. 1993;328:1002-1006.
3. Santini G, Salvagno L, Leoni P, et al. VACOP-B versus VACOP-B plus autologous bone marrow transplantation for advanced diffuse non-Hodgkin's lymphoma: results of a prospective randomized trial by the non-Hodgkin's Lymphoma Cooperative Study Group. J Clin Oncol. 1998;16:2796-2802.
4. Haioun C, Lepage E, Gisselbrecht C, et al. Survival benefit of high-dose therapy in poor-risk aggressive non-Hodgkin's lymphoma: final analysis of the prospective LNH87-2 protocol-a groupe d'Etude des lymphomes de l'Adulte study. J Clin Oncol 2000;18:3025-3030.
5. Kluin-Nelemans HC, Zagonel V, Anastasopoulou A, et al. Standard chemotherapy with or without high-dose chemotherapy for aggressive non-Hodgkin's lymphoma: randomized Phase III EORTC study. J Natl Cancer Inst. 2001;93:22-30.
6. Gisselbrecht C, Lepage E, Molina T, et al.; Groupe d'Etude des Lymphomes de l'Adulte. Shortened first-line high-dose chemotherapy for patients with poor-prognosis aggressive lymphoma. J Clin Oncol. 2002;20:2472-2479.
7. Kaiser U, Uebelacker I, Abel U, et al. Randomized study to evaluate the use of high-dose therapy as part of primary treatment for "aggressive" lymphoma. J Clin Oncol. 2002;20:4413-4419.
8. Martelli M, Gherlinzoni F, De Renzo A, et al. Early autologous stem-cell transplantation versus conventional chemotherapy as front-line therapy in high-risk, aggressive non-Hodgkin's lymphoma: an Italian multicenter randomized trial. J Clin Oncol. 2003;21:1255-1262.
9. Milpied N, Deconinck E, Gaillard F, et al.; Groupe Ouest-Est des Leucemies et des Autres Maladies du Sang. Initial treatment of aggressive lymphoma with high-dose chemotherapy and autologous stem cell support. N Engl J Med. 2004; 350:1287-1295.
10. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6:1562-1568.
11. Hryniuk WM, Goodyear M. The calculation of received dose intensity. J Clin Oncol. 1990;8:1935-1937.
12. Pocock SJ. Clinical trials. Chichester, UK: John Wiley & Sons, 1983.
13. Wheeler C, Antin JH, Churchill WH, et al. Cyclophosphamide, carmustine, and etoposide with autologous bone marrow transplantation in refractory Hodgkin's disease and non-Hodgkin's lymphoma: a dose-finding study. J Clin Oncol. 1990;8:648-656.
14. Pfreundschuh M, Trumper L, Kloess M, et al.; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of young patients with good-prognosis (normal LDH) aggressive lymphomas: results of the NHL-B1 trial of the DSHNHL. Blood. 2004;104:626-633.
15. Pfreundschuh M, Trumper L, Kloess M, et al.; German High-Grade Non-Hodgkin's Lymphoma Study Group. Two-weekly or 3-weekly CHOP chemotherapy with or without etoposide for the treatment of elderly patients with aggressive lymphomas: results of the NHL-B2 trial of the DSHNHL. Blood. 2004;104:634-41.
16. Stoppa AM, Bouabdallah R, Chabannon C, et al. Intensive sequential chemotherapy with repeated blood stem cell support for untreated poor prognosis non-Hodgkin's lymphoma. J Clin Oncol. 1997;15:1722-1729.
17. Miller TP, Grogan TM, Dahlberg S, et al. Prognostic significance of the Ki-67-associated proliferation antigen in aggressive non-Hodgkin's lymphoma: a prospective Southwest Oncology Group Trial. Blood. 1994;83:1460-1466.
18. Strehl J, Mey U, Glasmacher A, et al. High-dose chemotherapy followed by autologous stem cell transplantation as first-line therapy in aggressive non-Hodgkin's lymphoma: a meta-analysis. Haematologica. 2003;88:1304-1315.
19. Gianni AM, Bregni M, Siena S, et al. High-dose chemotherapy and autologous bone marrow transplantation compared with MACOP-B in aggressive B-cell lymphoma. N Engl J Med. 1997;336:1290-1297.
20. Pfreundschuh M, Truemper L, Gill D, et al. First analysis of the completed Mabthera International (Mint) trial in young patients with low-risk diffuse large b-cell lymphoma (DLBCL): addition of rituximab to a CHOP-like regimen significantly improves outcome of all patients with the identification of a very favorable subgroup with IPI = O and no bulky disease [abstract 157]. Blood. 2004;104:48a.
21. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346:235-242.